Is PHIOW or EQR a better dividend investment in 2026?

PHIOW currently yields 8620.69% with a 5% 5-year dividend growth rate. EQR yields 4.73% with 5% growth. The better choice depends on your goal: PHIOW offers higher current income.

What is the dividend yield difference between PHIOW and EQR?

PHIOW has a forward dividend yield of 8620.69% ($2.00/share annually). EQR yields 4.73% ($2.77/share annually). The yield gap is 8615.96 percentage points.

Home › Compare › PHIOW vs EQR

PHIOW vs EQR: Dividend Comparison 2026

PHIOW yields 8620.69% · EQR yields 4.73%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PHIOW wins by $12793007580007856.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PHIOW

● Live price

8620.69%

Share price

$0.02

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$12793007580007856.00M

Annual income

$12,507,597,271,400,990,000,000.00

Full PHIOW calculator →

EQR

● Live price

4.73%

Share price

$58.58

Annual div

$2.77

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$40.5K

Annual income

$3,819.61

Full EQR calculator →

Portfolio growth — PHIOW vs EQR

📍 PHIOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PHIOW	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PHIOW + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PHIOW pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHIOW

Annual income on $10K today (after 15% tax)

$732,758.62/yr

After 10yr DRIP, annual income (after tax)

$10,631,457,680,690,841,000,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$401.93/yr

After 10yr DRIP, annual income (after tax)

$3,246.67/yr

At 15% tax rate, PHIOW beats the other by $10,631,457,680,690,841,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHIOW + EQR for your $10,000?

PHIOW: 50%EQR: 50%

100% EQR50/50100% PHIOW

Portfolio after 10yr

$6396503790003928.00M

Annual income

$6,253,798,635,700,495,000,000.00/yr

Blended yield

97.77%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PHIOW

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-9.1

Piotroski

2/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+20.1% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHIOW buys

EQR buys

No recent congressional trades found for PHIOW or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPHIOWEQR

Forward yield	8620.69% ✓	4.73%
Annual dividend / share	$2.00	$2.77 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$12793007580007856.00M ✓	$40.5K
Annual income after 10y	$12,507,597,271,400,990,000,000.00 ✓	$3,819.61
Total dividends collected	$12773964733154094.00M ✓	$16.9K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Hold

Year-by-year: PHIOW vs EQR ($10,000, DRIP)

Year	PHIOW Portfolio	PHIOW Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$872,769	$862,068.97	$11,248	$547.57	+$861.5K → PHIOW
2	$71,250,409	$70,316,545.72	$12,701	$666.53	+$71.24M → PHIOW
3	$5,441,140,196	$5,364,902,258.92	$14,405	$814.59	+$5441.13M → PHIOW
4	$388,717,812,241	$382,895,792,231.73	$16,413	$999.84	+$388717.80M → PHIOW
5	$25,980,665,800,186	$25,564,737,741,087.56	$18,795	$1,232.92	+$25980665.78M → PHIOW
6	$1,624,683,420,105,904	$1,596,884,107,699,705.00	$21,639	$1,527.95	+$1624683420.08M → PHIOW
7	$95,065,580,496,684,460	$93,327,169,237,171,150.00	$25,057	$1,903.80	+$95065580496.66M → PHIOW
8	$5,205,346,525,995,166,000	$5,103,626,354,863,713,000.00	$29,197	$2,385.87	+$5205346525995.14M → PHIOW
9	$266,738,606,174,640,700,000	$261,168,885,391,825,900,000.00	$34,250	$3,008.70	+$266738606174640.66M → PHIOW
10	$12,793,007,580,007,855,000,000	$12,507,597,271,400,990,000,000.00	$40,467	$3,819.61	+$12793007580007856.00M → PHIOW

PHIOW vs EQR: Complete Analysis 2026

PHIOW — Stock

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Full PHIOW Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this PHIOW vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHIOW vs SCHD PHIOW vs JEPI PHIOW vs O PHIOW vs KO PHIOW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.